Aug 26 (Reuters) – Eli Lilly (LLY.N), opens new tab said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in patients without diabetes sent company shares tumbling.
Shares of the drugmaker rose nearly 4% to $722 in early trading.
The once-daily pill also helped 75% of patients who received the highest dose of orforglipron lower their A1C level – a measure of blood sugar over time – to at or below 6.5%, Lilly said, which is below the American Diabetes Association’s target of less than 7% for most adults.
Analysts said the data was in line with expectations, clearing an overhang for orforglipron’s U.S. marketing application and potential launch next year.